Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines
Open Access
- 28 April 2000
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 14 (5) , 841-844
- https://doi.org/10.1038/sj.leu.2401770
Abstract
Bisphosphonates (BPs) are commonly used in the treatment of myeloma-associated osteolytic lesions. Recent reports have suggested that BPs may also exert direct antitumor effects on myeloma cells. Here, we show that the treatment of myeloma cell lines with the combination of the potent BP zoledronate and dexamethasone inhibits cell growth and synergistically induces apoptotic cell death, providing a rationale for potential applications in vivo.Keywords
This publication has 20 references indexed in Scilit:
- A randomized trial of the effect of clodronate on skeletal morbidity in multiple myelomaBritish Journal of Haematology, 1998
- THE POTENTIAL OF FARNESYLTRANSFERASE INHIBITORS AS CANCER CHEMOTHERAPEUTICSAnnual Review of Pharmacology and Toxicology, 1997
- Measurement of apoptotic cells in peripheral bloodCytometry, 1995
- Excessive bone resorption in human plasmacytomas: direct induction by tumour cells in vivoBritish Journal of Haematology, 1995
- Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compoundJournal of Bone and Mineral Research, 1994
- Osteoclast inhibition for the treatment of bone metastasesCancer Treatment Reviews, 1993
- Features of apoptotic cells measured by flow cytometryCytometry, 1992
- Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.Journal of Clinical Investigation, 1991
- BisphosphonatesDrugs, 1991
- Activation of protein kinase isozymes by cyclic nucleotide analogs used singly or in combinationEuropean Journal of Biochemistry, 1985